Business Club, December 7. Although my country's pharmaceutical market has great potential，but more dispersed，To win the initiative in the field of product sales，Many foreign -funded enterprises have adopted a step -by -step strategy。In addition to continuing in Beijing、Shanghai、Guangzhou and others accounting for about 21%of the national pharmaceutical market share to consolidate the site，Continuous expansion intensity in second -tier cities。
In recent years，Foreign enterprises, especially multinational enterprises, have launched various forms of investment actions in the field of Chinese pharmaceuticals，Expansion trends are increasingly obvious，The main way to strive for market dominance is the most attractive to mergers and acquisitions，Quantity and scale increase year by year，Its main features are:
M & A manufacturers win cost advantages
Current，Many multinational pharmaceutical companies in order to obtain scale benefits in the production of non -patented drugs，Reduce cost，Continuous mergers and reorganization，Its main goal is my country's large manufacturer。
November 2004，Dutch Emman Group (DSM) said that he wants to establish a joint venture for the production of penicillin with North China Pharmaceutical，Investment of US $ 164 million and an international first -class production line worth $ 84 million。For Disman，Chinese medicine has low production costs and resource advantages，There is a strong production capacity，You can use the cost advantage of Chinese medicine to produce high -quality and low -cost raw medicines for it，You can use its influence in the Chinese market，Strong entering Chinese vitamins、High -end market for antibiotics and drugs。Because this case has not been finally approved，Otherwise, it will become the largest M & A in China in China。
September 2005，Malaysian pharmaceutical companies acquired 40%of stake sports betting appthe stake betting appequity of Wuxi Huayuan Changfu Pharmaceutical for $ 5.69 million。The same year，Japanese antibiotic enterprise Meiji Fruit Co., Ltd. invested 3 billion yen and Lubang joint venture to produce medical materials and antibiotics and antibiotics。October 2007，Germany Bayer acquired 3 OTC brand medicines such as His Majesty of Dongsheng Technology for 1.072 billion yuan。Dongsheng Technology OTC business accounts for more than 80%of its main income，This merger and acquisition actually removed most of its rivers and mountains。November 2008，The largest medical weapon manufacturing company in the UK Smith Medical M & A Zhejiang University Medical Instrument Co., Ltd.，thus occupying the largest share of the domestic medical injection pump market。
Accelerate entering the second and third -tier cities
Although my country's pharmaceutical market has huge potential but is more decentralized，To win the initiative in the field of pharmaceutical products，Many foreign companies have adopted a step -by -step strategy。In addition to continuing in Beijing、Shanghai、Guangzhou and others accounting for about 21%of the national pharmaceutical market share to consolidate the site，Continuously increasing the expansion of second -tier cities that account for about 37%of the market share。
in one、Second -tier cities，Big hospitals above 500 beds，Small and medium -sized hospitals below 300 beds，Foreign figures can be seen often，and the sales team continues to expand。Current，Foreign companies have stared closely at the community that must be focused on development，Started a strong sales training。Three -tier cities that account for about 16%of the national pharmaceutical market，Since most foreign companies adopt the model based on the sales of middlemen，Do not send sales representatives directly to the hospital，Therefore, the hospital sales channel cannot be controlled for a long time。So，Foreign companies have adjusted marketing models，Direct sales representative，This trend is particularly obvious。
According to my country's enrollment commitment，From December 11, 2004, the field of medical circulation is fully open to the public，Foreign companies can engage in purchasing in China、Storage、Transport、All business activities including retail and after -sales service。For foreign companies，Leading companies in the market through mergers and acquisitions，Can achieve avoiding obstacles，Save access cost，and then fully occupy the purpose of marketing channels。
December 2004，American American Medicine for $ 1 million，Vowerous acquisition of Beijing Wanwei Pharmaceutical，Become the first foreign company to enter the field of pharmaceutical distribution in my country。July 2005，Dr. U.S. US $ 200 million，Get 55%of the shares of Shandong Zhengda Furida stake sports betting appPharmaceutical。Stake Sports BettingThis acquisition of Docian，Re -combine the marketing network of Shandong Zhengda with its ophthalmology brand，greatly accelerated the expansion of doctors in the Chinese ophthalmology market。April 2005，Japanese Sumitomo Commercial Co., Ltd.、Sumitomo Commercial (China) and Henan Tianfang Pharmaceutical signed the "Share Purchase Agreement"，Japanese can use the huge sales channels of Tianfang Pharmaceuticals to directly enter the field of drug distribution in the province of Henan.。2008，General Group acquired Tianfang Pharmaceutical，After that, the resident business decision decided to withdraw。January 2007，Alliance Boots, one of the largest pharmaceutical distribution in the UK and one of the retail companies，Announced that a joint venture with Guangzhou Medical Co., Ltd., Guangzhou Pharmaceutical Co., Ltd.，Union Bo Zi has 50%equity，In recent years, its marketing network in China has quickly rolled out。May 2007，Shanghai Pharmaceutical Co., Ltd. also established a joint venture with Japan's largest hospital drug distributor Ling Qian Co., Ltd.，Japanese side owns 50%of the company's equity。October 2008，Northern Europe's largest industrial holding company Sweden Sweden Yinruida Group subsidiary Yin Tuo Asia invested more than $ 80 million to invest in Hunan people，Enter the pharmaceutical retail terminal。
aiming at biomedical seizing research and development advantages
Current，Although a few developed countries occupy the absolute proportion of the global biomedical market，But with the continuous subdivision of biotechnology research and development，Even large multinational biomedical companies are difficult to complete all the research and development of research and development。my country's biopharmaceutical industry starts late，But with first -class scientific research talents and results、Rich disease resources、Low clinical trial costs and efficient logistics and distribution networks。
In recent years，Foreign -funded enterprises have shifted to the key of mergers and acquisitions to outstanding research and development capabilities、Emerging biopharmaceutical companies with broad prospects for product market development and strong sustainable development capabilities。July 2003，US Best Investment 15 million U.S，Specializing in the production of intravenous anesthesia bisopoline that is currently widely used in my country。Best is a world -renowned medical product and service company，Divineophenol injection independently developed by Libang Pharmaceuticals has been included in the country's "Eighty -Five"、"Ninth Five -Year Plan" research project。M & A can allow the United States to use Xi'an Libang's existing advantages，Reduce the cost of research and development of new stake sports betting appproducts，stake online sports bettingperfect product line，Create conditions for entering my country's biomedical market。
Set the R & D Center to achieve advantage grafting
In recent years，Roche、Astrikang、GSK、Lili Lili、Bayer and other multinational companies have set up a R & D center in China，The R & D advantage with the talents of my country、Clinical trial advantages Realize grafting。
At present，The main features of the R & D institution of the multinational company，The first is to gradually develop transition from non -core technology development to core technology development。Second, the research and development institutions are mainly concentrated in Beijing、Shanghai、Tianjin、Wuxi and other scientific research forces with concentrated areas。Third, most of them are non -independent legal persons。Most of the multinational companies tend to set up an illegal research and development institution in China，To facilitate management and control，easy to commercialize the research and development results as soon as possible。Fourth, the technical overflow effect is not obvious。Staff personnel of foreign -funded research and development institutions are relatively stable，A small number of personnel flow is also limited to foreign companies，Strict patent protection，Its scientific research results rarely flow to domestic enterprises。
October 2008，Sanofi Avant began to expand research and development institutions in my country，Expand the R & D scale，The R & D center settled in Beijing will become the company's fourth largest R & D center in the world，Business involves drug foundation development、Clinical Studies、Biological statistics and programming、Clinical data management and registration, etc.，and will strengthen cooperation with the Shanghai Institute of Life Sciences, the Chinese Academy of Sciences。early 2009，Bayer Xianling invested 100 million euros in Beijing to establish a global research and development center，Make the center the fourth largest R & D base in the world in Bayer Medical Care。August，Novartis Ultimate Innovation Pharmaceutical Yistein is listed in China，The main attack target is my country's grass -roots medical market，and invest in more than 250 million US dollars，Establishing raw and drug development and production bases at Changshu, Jiangsu。September，Astrikang Innovation Center established in Zhangjiang High -tech Park, Shanghai，engaged in R & D and innovative drugs，also said that the annual business growth rate in my country in the next 10 years is locked at 22%。October，Germany Bollinger Yingehan, which has always been low -key, announced that it will add 100 million euros，It is mainly used to expand production capacity and build a new R & D center。
stake online sports bettingBettering stake online sports bettinginto the traditional Chinese medicine market
Chinese medicine is the most independent intellectual property product in my country。With the extensive rise of European and American alternative therapies in recent years and the unique effect of botanical medicines, it has been re -recognized，More and more foreign pharmaceutical companies are looking for new traditional medicine products with market selling points in China。Because my country's government has strict restrictions on foreign investment in the field of Chinese medicine，It is prohibited from the processing of Chinese medicinal materials that are included in the country's protection resources，Traditional Chinese Medicine Drinking Film、Production technology and the production of Chinese medicine secret recipe products，So，Many multinational companies hope to use the investment -type mergers and acquisitions of Chinese medicine companies，Bettering of "Wipe Border"，Get scarce Chinese medicine resources，Occupy the market share of traditional Chinese medicine。
May 2004，U.S. Oriental Biotechnology acquired 100%of the equity of 100%equity of Heilongjiang Songhuajiang Pharmaceutical, which is mainly producing traditional Chinese medicine。March 2005，US Rihui Group invested 15 million US dollars to Hua Liang Pharmaceutical，Specializing in the development of Jilin Changbai Mountain "North Medicine" resources。Huasiang Pharmaceutical with a strong foundation has a GAP planting base of 2040 acres in the hinterland of Changbai Mountain，M & A provides a favorable platform for Rihui Group to enter the field。July 2009，Sino -U.S. Skills and Tianjin Sino -Singapore Pharmaceutical Da Rintang Traditional Chinese Medicine Factory cooperation，Involved in the field of Chinese patent medicine sales。(the author is the director of the General Department of the Medical Insurance Chamber of Commerce)
